1. Introduction {#sec1}
===============

*Crocus sativus* L. (*C. sativus*) is a perennial herb member of the Iridaceae family, the line of Liliaceae. This plant is cultivated in many countries such as Azerbaijan, China, France, Greece, Egypt, India, Iran, Israel, Italy, Mexico, Morocco, Spain, and Turkey. Its product is the well-known spice called saffron. Saffron, in filaments, is the dried dark-red stigmas of*C. sativus* flower \[[@B38]\]. One stigma of saffron weighs about 2 mg and each flower has three stigmata; 150000 flowers must be carefully picked one by one to obtain 1 kg of spice. Saffron has a distinct colour, flavour, and odour. It is used both as a spice for flavouring and colouring food preparations and as a perfume. The stigmas of it are also used in folk medicine as an anticatarrhal, eupeptic, antispasmodic, expectorant, emmenagogue, and nerve sedative (for review see \[[@B60]\]). Interestingly, saffron has widely been used in the Persian traditional medicine for memory problems \[[@B5]\].

2. Chemistry of*C. sativus* {#sec2}
===========================

Chemical analysis of*C. sativus* stigmas has shown the presence of about 150 volatile and nonvolatile compounds; fewer than 50 constituents, however, have been identified so far \[[@B71]\]. The volatiles consist of more than 34 components that are terpenes, terpene alcohols, and their esters among which safranal is the main component. Nonvolatile compounds comprise crocins, crocetin, picrocrocin safranal, and flavonoids (quercetin and kaempferol) \[[@B43]\].

Particularly, crocins, glucosyl esters of crocetin, are water-soluble carotenoids and are responsible for saffron\'s characteristic colour. Picrocrocin, glycoside of safranal, is responsible for the bitter taste of the spice and is precursor of safranal. Safranal, the main component of the distilled essential oil, is a monoterpene aldehyde, responsible for its characteristic aroma \[[@B39], [@B69]\].

3. Pharmacological Actions of*C. sativus* and Its Constituents {#sec3}
==============================================================

3.1. Safety Studies {#sec3.1}
-------------------

Toxicity studies have demonstrated that the hematological and biochemical parameters were within normal range in mice treated with saffron extracts \[[@B50]\]. It has also been reported that the oral LD~50~ of saffron was 20.7 g/kg administered as decoction in mice \[[@B1]\]. Further, a recent work investigated either the acute (up to 3 g, both orally (p.o.) and intraperitoneally (i.p.)) or the subchronic effects of crocin (15--180 mg/kg, i.p.) in different biochemical, hematological, and pathological parameters in rodents. The results of this study evidenced that at pharmacological doses crocin did not display appreciable toxicity \[[@B34]\].

Interestingly, the findings of clinical studies suggest that both*C. sativus* extracts and crocin display a relative safe and normal pharmacological profile. Specifically, in a double-blind, placebo-controlled trial conducted on healthy volunteers a one-week treatment with saffron (200--400 mg/day) did not evidence particular alterations \[[@B46]\]. Moreover, the results of another double-blind, placebo-controlled study performed in healthy volunteers also showed that administration for one month of crocin (20 mg/day) did not elicit significant alterations of different hematological, biochemical, hormonal, and urinary parameters recorded \[[@B47]\].

3.2. Effects of*C. sativus* and Its Constituents on Cancer Therapy, Hepatotoxicity, Nociception, Inflammation, and Cardiovascular System {#sec3.2}
----------------------------------------------------------------------------------------------------------------------------------------

Preclinical pharmacological studies have demonstrated that*C. sativus* crude extracts and purified chemicals possess antitumour effects (e.g., \[[@B50], [@B63], [@B68]\]). Saffron and its ingredients display antinociceptive and anti-inflammatory properties \[[@B27]\], reduce atherosclerosis \[[@B20]\] and hepatic damage \[[@B70]\], counteract hyperlipidaemia \[[@B42]\], protect from myocardial injury \[[@B16]\], and display antihypertensive action \[[@B17], [@B37]\]. The effects exerted by saffron and its components in the aforementioned pathologies were also extensively discussed in different reviews (e.g., \[[@B60], [@B2]--[@B9]\]).

The outcome of these preclinical studies indicates that*C. sativus* and its components exert a beneficial action in several pathologies. It is important to underline, however, that up to our days there is no clinical information on the potential efficacy of saffron and its constituents in the aforementioned pathologies. Future research aiming to prove the efficacy of this spice observed in preclinical experimentations in humans is required.

3.3. Effects of*C. sativus* and Its Constituents on Central Nervous System (CNS) {#sec3.3}
--------------------------------------------------------------------------------

### 3.3.1. Affective Disorders {#sec3.3.1}

Experimental evidence indicated that crocins displayed an anxiolytic-like effect in procedures assessing anxiety and obsessive compulsive disorder (OCD) in rats \[[@B21], [@B58]\]. Interestingly, a study carried out in mice suggested that the aqueous extracts of*C. sativus* and safranal but not crocin have anxiolytic and hypnotic effects \[[@B33]\].

*C. sativus* and its active components crocin and safranal have shown antidepressant-like effects in animal models of depression \[[@B28]\]. Importantly, clinical research reinforced preclinical results and proposed that saffron is efficacious for the treatment of mild-to-moderate depression \[[@B4], [@B51]\]. In this context, it has been shown that saffron antagonized sexual dysfunction induced by the selective serotonin reuptake inhibitor fluoxetine in humans \[[@B40], [@B45]\].

Recently, it has been reported that crocins were found effective in antagonizing psychotomimetic effects in rats related to the hypofunction of the glutamatergic system. These results suggest that further studies should be carried out aiming to elucidate whether or not these active components of saffron might constitute a potential candidate for the treatment of schizophrenia \[[@B22]\].

### 3.3.2. Anticonvulsant Activity, Neurodegeneration {#sec3.3.2}

Studies performed in rodents revealed a certain anticonvulsant activity of aqueous and ethanolic extracts of*C. sativus* and its active component safranal \[[@B29], [@B31]\]. Saffron and its active constituents affect a number of different neural processes, for example, conferred neuroprotection in a rat model of Parkinson disease (PD) \[[@B3]\]. In addition,*in vitro* and*in vivo* preclinical experimentations propose a protective role for saffron extracts, crocin and safranal, in cerebral ischemia \[[@B30]--[@B73]\].

4. Effects of*C. sativus* and Its Constituents on Cognition {#sec4}
===========================================================

Dementia is one of the major medical illnesses at older age, where the patient\'s language, attention, and memory are compromised. Amnesia is among the typical features of dementia and is characterized by the inability to form memories or total or partial loss of memory secondary to cerebral malfunction following degenerative diseases such as Alzheimer\'s disease (AD), cerebral infections such as herpes or encephalitis, traumatic injuries such as stroke, alcohol, or drug abuse, emotional events such as psychological trauma, and affective disorders (schizophrenia).

AD is the most common form of dementia. The prevalence of AD is strongly correlated with increasing age and is a consequence of progressive neurodegeneration occurring over a period of several years. The neurodegeneration leads to a gradual decline in cognitive, functional, and behavioural processes, producing characteristic symptoms such as memory loss, confusion agitation, and difficulties performing the activities of daily living \[[@B14]\].

No conventional or alternative therapy is currently available to cure amnesia. Current therapeutic strategies for amnesia are mainly focused on enhancing or restoring cerebral circulation, restoring the cholinergic neurotransmission and scavenging free radicals. In the management of amnesia, as well as AD, sustained treatment with acetylcholinesterase (AChE) inhibitors including donepezil, rivastigmine, galantamine, tacrine, and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine has been used \[[@B26], [@B36]\]. However, these drugs have modest efficacy and induce severe side effects \[[@B19], [@B61]\].

4.1. Preclinical Studies {#sec4.1}
------------------------

An overview of the preclinical literature regarding the effects of*C. sativus* and its constituents on memory is provided in [Table 1](#tab1){ref-type="table"}. Oral administration of extracts of*C. sativus* (125--500 mg/kg) reversed ethanol but not scopolamine-induced memory impairments in the passive avoidance paradigm in mice \[[@B72]\]. Similarly, administration of the active constituent of*C. sativus* crocin (50--200 mg/kg, p.o.) but not picrocrocin counteracted ethanol-induced performance deficits in the mice in the same memory test \[[@B67]\]. In addition, a single intraperitoneal injection of*C. sativus* extracts (30--60 mg/kg) antagonized scopolamine-induced performance deficits in the passive avoidance task and extinction of recognition memory in rats \[[@B56]\].

The active components of saffron crocins (15--30 mg/kg, i.p.) counteracted scopolamine-induced performance deficits in the novel object recognition test (NORT) and in the radial water maze task in rats. NORT and radial water maze task are procedures assessing recognition and spatial memory, respectively, in rodents \[[@B57]\]. The findings of the latter two studies \[[@B56], [@B57]\] clearly support a functional interaction between*C. sativus* and crocins with the cholinergic system. Moreover, chronic application of crocin (15--30 mg/kg, i.p.) attenuated performance deficits produced by administration of streptozotocin (STZ) in the passive avoidance and the Y-maze procedures in rats \[[@B41]\].

Chronic treatment with*C. sativus* extracts (60 mg/kg, i.p.) reversed age-related memory deficits in the 20-month-old mouse evidenced in the passive avoidance paradigm \[[@B55]\]. In a procedure evaluating spatial memory in rodents (Morris water maze) it was found that a 21-day treatment with*C. sativus* extracts (30 mg/kg, i.p.) or crocin (15--30 mg/kg, i.p.) reversed spatial learning and memory deficits produced by chronic stress in rats \[[@B24]\].

Chronic administration of*C. sativus* extracts (100--250 mg/kg, i.p.) and crocin (5--30 mg/kg, i.p.) was able to counteract spatial memory deficits in a model of cerebral ischemia in rats \[[@B35]\]. Using the same procedure and a chronic regimen of administration of crocin (100 mg/kg, p.o.), Naghizadeh et al. showed a protective effect of this constituent of*C. sativus* on spatial memory deficits and oxidative stress produced by STZ in rats \[[@B49]\]. Conversely, a study aiming to investigate potential neuroprotective effect of*C. sativus* extracts (60 mg/kg, i.p. chronically) against established aluminium (AlCl~3~) toxicity failed to attenuate the AlCl~3~-induced memory deficits in the passive avoidance task in mice. Reportedly, in this context, saffron treatment was found to attenuate different biochemical markers of brain functions which were altered by the AlCl~3~-induced toxicity \[[@B44]\].

Finally, a single injection of crocins (15--30 mg/kg, i.p.) reversed recognition memory deficits produced by the NMDA receptor antagonist ketamine in rats eliciting thus the implication of this active constituent of*C. sativus* in schizophrenia-related cognitive deficits. These findings also propose a functional interaction between crocins and the glutamatergic system \[[@B22]\]. In this context, it has been reported that acute systemic administration of safranal reduced kainic acid-induced increase of extracellular glutamate concentrations in the rat hippocampus \[[@B32]\] and*C. sativus* extracts inhibited glutamatergic synaptic transmission in rat cortical brain slices \[[@B10]\]. Collectively, these results suggest that this reduction of glutamate levels by saffron and its constituents might be critical for the beneficial action exerted by crocins on ketamine-induced behavioural deficits.

4.2. Clinical Studies {#sec4.2}
---------------------

An overview of the clinical literature regarding the effects of*C. sativus* on cognition is provided in [Table 2](#tab2){ref-type="table"}. Up to now, few trials were carried out aiming to assess the effects of saffron in humans suffering from memory disorders.

A first study was carried out in 46 patients with mild-to-moderate AD. Patients received saffron (30 mg/day, p.o.) or placebo for 16 weeks. The results of this randomized, double-blind study suggested that saffron might be both safe and effective in mild-to-moderate AD patients \[[@B6]\].

A subsequent clinical trial of the same group of scientists was designed and performed aiming to evaluate in a larger number of patients (55 patients participated) suffering from mild-to-moderate AD the potential effects of*C. sativus* on cognition. In this 22-week, multicentre, double-blind controlled trial participants randomly were assigned to receive saffron (30 mg/day, p.o.) or the reference compound, the AChE inhibitor donepezil (10 mg/day, p.o.). The findings of this phase II study provided preliminary evidence of a possible therapeutic effect of*C. sativus* in AD. Specifically, saffron\'s efficacy was not different than that of donepezil and some adverse effects that occurred after donepezil treatment (vomiting) were absent in the saffron-treated patients \[[@B7]\].

Finally, a recent clinical work compared the efficacy and safety of*C. sativus* with the NMDA receptor antagonist memantine in patients suffering from moderate-to-severe AD. In this one-year, double-blind clinical trial participated 68 patients which were randomly assigned to receive saffron (30 mg/day, p.o.) or memantine (20 mg/day, p.o.). The results of this study did not reveal any difference either in terms of efficacy or in terms of safety between patients that received either memantine or saffron \[[@B18]\].

5. Mechanism of Action of*C. sativus* and Its Constituents {#sec5}
==========================================================

The mechanism(s) underlying effects of saffron and its active constituents on cognition is still a matter of investigation. Among the potential mechanisms, the promotion of long-term potentiation (LTP), the antiamyloidogenic activity, its inhibitory action on the AChE activity, and their potent antioxidant properties are proposed to explain their action on cognition.

Specifically, LTP is an activity-dependent form of modified transmission efficacy at synapses \[[@B12]\]. This type of neuronal plasticity, first shown in the hippocampus, in the meanwhile, has been found to occur in various brain regions, thus being a widespread phenomenon in the CNS. In addition, learning and memory occur as a result of changes in the efficacy of synaptic transmission. Reportedly, in this context, it has been revealed that crocin promoted the hippocampal LTP \[[@B66]\].

Aggregation and deposition of amyloid-*β* (A*β*) peptides is the main molecular process underlying AD. It has been shown that saffron stigmas\' extract interacts with these peptides and prevented A*β* fibrillogenesis and amyloid formation in an*in vitro* model of AD \[[@B54]\]. In addition, the results of*in vitro* enzymatic and molecular docking studies indicate that*C. sativus* and crocetin but not safranal inhibit AChE by binding in two different loci, the catalytic center and the peripheral anionic sites. This AChE inhibitory activity displayed by*C. sativus* and crocetin promotes an increase of the synaptic acetylcholine levels, a neurotransmitter critically involved in cognitive functions \[[@B23]\].

Consistent experimental evidence proposes a key role for oxidative stress in the pathogenesis of different neurodegenerative disorders including AD and PD and in pathological conditions such as brain injuries \[[@B13]--[@B64]\]. In addition, although the pathogenesis of schizophrenia remains unknown, a possible relationship between oxidative stress and the disease has also been proposed \[[@B11], [@B59]\]. In support of this view, it was reported that ketamine increased oxidative stress in the brain of rats \[[@B15]\]. Therefore, an alternative hypothesis to explain the beneficial action exerted by saffron and crocin in memory disorders is based on the well-known antioxidant properties of*C. sativus* and its constituents. In line with this, a wide variety of studies revealed the antioxidant properties of*C. sativus* \[[@B62], [@B55], [@B24], [@B44], [@B54]\], crocin \[[@B73], [@B24], [@B48]--[@B65]\], crocetin \[[@B55]\], and safranal \[[@B30]\].

6. Conclusions {#sec6}
==============

Accumulating evidence indicates that*C. sativus* and its major component crocin are significantly involved in cognition. Preclinical studies demonstrated their efficacy in attenuating memory disorders in animal models related to AD, cerebral injuries, or schizophrenia.

Clinical research has evaluated the efficacy of saffron, but not of crocin, in a narrow range of memory disorders (AD). The results indicated that its effects on cognition, although modest, were not different than those expressed by donepezil and memantine. In this context, it is important to emphasize the good safety profile of saffron which was revealed in all clinical experimentations. There is no information, however, on the potential efficacy of saffron and crocin in memory disorders which occurred in other pathologies such as brain ischemia, traumatic brain injury, and cognitive deficits related to schizophrenia. The potential role of saffron and crocin as adjunctive agents, in combination with an AChE inhibitor or memantine, for the treatment of memory disorders has not been investigated so far. Future research should address these issues.
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###### 

Effects of*Crocus sativus* L. and its constituents on cognition. Preclinical studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Species      Agent                 Dose range              Route                  Memory task                  Effect                                                                                                                                                                                   Reference
  ------------ --------------------- ----------------------- ---------------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Mouse        CsE \                 125--250--500 mg/kg \   p.o. acute \           Passive avoidance            Reversed ethanol but not scopolamine-induced deficits                                                                                                                                    \[[@B72]\]
               Ethanol \             30%, 10 mL/kg \         p.o. acute \                                                                                                                                                                                                                                 
               Scopolamine           0.5 mg/kg               i.p. acute                                                                                                                                                                                                                                   

  Mouse        Crocin \              50--100--200 mg/kg \    p.o. acute \           Passive avoidance            Crocin but not picrocrocin reversed ethanol-induced deficits                                                                                                                             \[[@B66]\]
               Picrocrocin \         50--100--200 mg/kg \    p.o. acute \                                                                                                                                                                                                                                 
               Ethanol               30--40%, 10 mL/kg       p.o. acute                                                                                                                                                                                                                                   

  Rat          CsE \                 10--30--60 mg/kg \      i.p. acute \           Novel object recognition \   Reversed (30--60 mg/kg) scopolamine-induced and delay-dependent memory deficits                                                                                                          \[[@B56]\]
               Scopolamine           0.75 mg/kg              s.c. acute             Passive avoidance                                                                                                                                                                                                     

  Rat          Crocins \             15--30 mg/kg \          i.p.\                  Novel object recognition \   Given acutely reversed scopolamine-induced recognition memory deficits, chronic treatment (5 days) counteracted scopolamine-induced performance deficits in the radial water maze task   \[[@B57]\]
               Scopolamine           0.2 mg/kg               s.c..                  Radial water maze                                                                                                                                                                                                     

  Rat          Crocin \              15--30 mg/kg \          i.p. chronic \         Y-maze \                     Chronic treatment (30 mg/kg, for three weeks) reversed streptozotocin-induced performance deficits in the Y-maze and passive avoidance task                                              \[[@B41]\]
               Streptozotocin        3 mg/kg                 i.c.v. acute           Passive avoidance                                                                                                                                                                                                     

  Aged mouse   CsE                   60 mg/kg                i.p. chronic           Passive avoidance            Chronic treatment (7 days) reversed age-related  \                                                                                                                                       \[[@B55]\]
                                                                                                                 memory deficits                                                                                                                                                                          

  Rat          CsE \                 30 mg/kg \              i.p. chronic \         Morris water maze            Chronic treatment (21 days) reversed chronic stress-induced\                                                                                                                             \[[@B24]\]
               Crocin                15--30 mg/kg            i.p. chronic                                        spatial memory deficits                                                                                                                                                                  

  Rat          CsE \                 50--100--250 mg/kg \    i.p. chronic \         Morris water maze            Chronic treatment (7 days) of CsE (100--250 mg/kg) and\                                                                                                                                  \[[@B35]\]
               Crocin                5--10--25 mg/kg         i.p. chronic                                        crocin reversed cerebral ischemia-induced spatial memory deficits                                                                                                                        

  Rat          Crocin \              100 mg/kg \             p.o. chronic  \        Morris water maze            Chronic treatment (21 days) reversed streptozotocin-\                                                                                                                                    \[[@B49]\]
               Streptozotocin        3 mg/kg                 i.c.v. (2 infusions)                                induced spatial memory deficits                                                                                                                                                          

  Mouse        CsE \                 60 mg/kg \              i.p. chronic \         Passive avoidance            Ineffective to reverse AlCl~3~-induced memory deficits                                                                                                                                   \[[@B44]\]
               Aluminium (AlCl~3~)   50 mg/kg                p.o. chronic                                                                                                                                                                                                                                 

  Rat          Crocins \             15--30 mg/kg \          i.p. acute \           Novel object recognition     Reversed ketamine-induced recognition memory deficits                                                                                                                                    \[[@B22]\]
               Ketamine              3 mg/kg                 i.p. acute                                                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CsE, *Crocus sativus*extracts; i.c.v., intracerebroventricularly; i.p., intraperitoneally; p.o., orally; s.c., subcutaneously.

###### 

Summary of clinical trials on *Crocus sativus* L., as treatment for AD.  

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Design of study   Duration of study   Severity of disease     Agent            Dose range    Route   Effect                                                             Reference
  ----------------- ------------------- ----------------------- ---------------- ------------- ------- ------------------------------------------------------------------ ------------
  Double-blind      16 weeks            Mild-to-moderate AD     *C. sativus*     30 mg/day     p.o.    Safe and with certain efficacy                                     \[[@B6]\]

  Double-blind      22 weeks            Mild-to-moderate AD     *C. sativus* \   30 mg/day \   p.o.\   Similar efficacy and better safety profile compared to donepezil   \[[@B7]\]
                                                                Donepezil        10 mg/day     p.o.                                                                       

  Double-blind      12 weeks            Moderate-to-severe AD   *C. sativus* \   30 mg/day \   p.o.\   Similar efficacy and safety profile compared to memantine          \[[@B18]\]
                                                                Memantine        20 mg/day     p.o.                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer\'s disease; *C. sativus*, *Crocus sativus* L.; p.o., orally.
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